Abalone Bio, Inc.
- UEI
- KKSHAJA41B56
- CAGE
- 7X2N3
- Primary NAICS
- Not on record
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- abalonebio.com
- Founded
- 2017
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Epigen Biosciences Inc. | San Diego, CA | 325199 All Other Basic Organic Chemical Manufacturing |
| Oncotrap Inc. | Chapel Hill, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Trellis Bioscience, Inc. | — | — |
| Artiam Bio Inc. | Cary, NC | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Amberstone Biosciences Inc. | Irvine, CA | — |
About the company
Abalone Bio, Inc., doing business as Abalone Bio Inc., is a biotechnology company specializing in the development of novel antibody therapeutics for various medical conditions. The company is registered to receive awards from the U.S. federal government and has been active in this capacity since August 2017. Abalone Bio utilizes its proprietary Functional Antibody Selection Technology (FAST) platform to discover and develop antibody-based drugs targeting G protein-coupled receptors (GPCRs). The company focuses on creating innovative treatments for pain management, inflammatory conditions, and fibrotic diseases. Abalone Bio is classified as a minority-owned, for-profit organization with Asian-Pacific American ownership.
Through federal grant awards, Abalone Bio has undertaken several research projects aimed at advancing its antibody therapeutics pipeline. The company has received funding from multiple institutes within the National Institutes of Health (NIH), including the National Institute on Drug Abuse (NIDA), the National Institute of Child Health and Human Development (NICHD), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These grants have supported the development of peripherally-restricted mu-opioid receptor agonist antibodies for pain relief with reduced side effects, cannabinoid 2 receptor (CB2) agonist antibodies for treating endometriosis-related pain and inflammatory bowel disease, and therapeutic antibodies for liver fibrosis and non-alcoholic steatohepatitis (NASH). The company's work involves creating stable cell lines, developing in vitro functional assays, evaluating antibody candidates in animal models, and advancing promising candidates towards clinical trials. Abalone Bio's research aims to address unmet medical needs by developing long-acting, specific, and potentially safer alternatives to traditional small molecule drugs for chronic conditions.
Quick answers
Is Abalone Bio, Inc. registered in SAM.gov?
Abalone Bio, Inc.'s SAM.gov registration expired on October 11, 2025.
What is Abalone Bio, Inc.'s most recent federal award?
Abalone Bio, Inc.'s most recent federal grant award is A peripherally restricted MOR agonist for effective pain management with reduced risks (R43DA060776), from National Institute on Drug Abuse (NIH), on April 1, 2024.
On GovTribe
See Abalone Bio, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors